tbuckley/cabot-search huggingface dataset:
Long-Term Safety of Dasatinib in Chinese Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib-Resistance or -Intolerance: Results from a 6-Year Follow-up of a Multicenter Phase II Study
Authors: Xiaojun Huang, Qian Jiang, Jianda Hu, Jianyong Li, Jie Jin, Fanyi Meng, Zhixiang Shen, Ting Liu, Depei Wu, Jianmin Wang, Jianxiang Wang
Journal: Blood (2016)
The Prognostic Role of Smac/DIABLO Protein Expression in Acute Myeloid Leukemia.
Authors: Agnieszka Pluta, Agata Wrzesien-Kus, Barbara Cebula, Anna Wolska, Anna Szmigielska-Kaplon, Magdalena Czemerska, Piotr Smolewski, Tadeusz Robak, Agnieszka Wierzbowska
Journal: Blood (2009)
Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs Analysis
Authors: Matthias Stelljes, Utz Krug, Dietrich Beelen, Jan Braess, Maria Cristina Sauerland, Achim Heinecke, Tim Sauer, Petra Tschanter, Gabriela B. Thoennissen, Hans-Jochem Kolb, Albrecht Reichle, Ernst Holler, Rainer Schwerdtfeger, Renate Arnold, Christof Scheid, Carsten Müller-Tidow, Bernhard J. Woermann, Wolfgang Hiddemann, Wolfgang E. Berdel, Thomas Büchner
Journal: Blood (2012)
The case of non-small cell lung cancer followed by lip lymphoproliferative disease after immunotherapy
Authors: Tomoaki Sonoda, Yuko Waseda, Shiro Iino, Yoshiaki Imamura, Mai Takeuchi, Yukihiro Umeda, Miwa Morikawa, Masaki Anzai, Tamotsu Ishizuka
Journal: Annals of Oncology (2019)
Pembrolizumab (pembro) in Mismatch Repair-Deficient (dMMR) Advanced Colorectal Cancer (CRC): KEYNOTE-164 Japan Subgroup
Authors: Hiroya Taniguchi, Hiroki Hara, Takayuki Yoshino, Kiwamu Akagi, Kohei Shitara, Toshiki Masuishi, Yasutoshi Kuboki, Takashi Shimamoto, Kenichi Ueki, Shi Rong Han, Kazuo Noguchi, Luis A Diaz
Journal: Annals of Oncology (2019)
Single-Stranded Oligonucleotide Binding to P-Selectin Inhibits Adhesion of Sickle Red Blood Cells and Leukocytes to Endothelial Cells in Sickle Cell Model Mice: Novel Therapeutics for Vaso-Occlusive Episodes.
Authors: Diana Gutsaeva, James Parkerson, Robert G Schaub, Jeffrey Kurz, Alvin Head
Journal: Blood (2009)
CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies,
Authors: Renee C Prins, Stephen Spurgeon, Jeffrey W Tyner, Luke B Fletcher, Abdusebur Jemal, Jade A Bryant, Russell T Burke, Bill H Chang, Tibor Kovacsovics, Brian J. Druker, Marc M Loriaux
Journal: Blood (2011)
Absence of Mutations of the Histone Methyltransferase Gene EZH2 In Splenic B-Cell Marginal Zone Lymphoma
Authors: Luz Martínez-Avilés, Marta Salido, Beatriz Bellosillo, Vera Adema, Ana Ferrer, Antonio Salar, Mar Garcia, Blanca Espinet, Lourdes Florensa, Carles Besses, Sergi Serrano, Francesc Sole
Journal: Blood (2010)
Next-Generation Sequencing Analysis of Clonal Hierarchy and Dynamics in T-Large Granular Lymphocyte Leukemia Suggests Emergence of STAT3 Clones within Pre-Existing Dominant T-Cell Repertoire Responses Otherwise Silenced in Normal Individuals
Authors: Peter W Chomczynski, Michael J. Clemente, Srinivasa Reddy Sanikommu, Alek d Nielsen, Cassandra M. Hirsch, Hanna Rajala, Mikkael A. Sekeres, Hetty E. Carraway, Satu Mustjoki, Alan E. Lichtin, Jaroslaw P Maciejewski
Journal: Blood (2016)
Association Between Busulfan First-Dose Pharmacokinetics and Outcome in Children Receiving Myeloablative Busulfan-Based Conditioning Before Unrelated Umbilical Cord Blood Transplantation for Malignancies
Authors: Henrique Bittencourt, Mohamed Aziz Rezgui, Samira Meziani, Marie-France Vachon, Catherine Desjean, Michel Duval, Yves Theoret, Maja Krajinovic, Marc Ansari
Journal: Blood (2012)
A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide: A Novel Preparative Regimen Prior to Autologous Peripheral Blood Stem Cell (PBSC) Transplantation in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma.
Authors: Sherif Farag, Lisa L Wood, Shivani Srivastava, Robert P. Nelson, Jennifer E. Schwartz, Elizabeth Cox, Rafat Abonour, Michael Robertson
Journal: Blood (2009)
Results of Phase II Study of Lenalidomide (L) {Revlimid®} in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
Authors: Asher Alban Chanan-Khan, Kena C. Miller, Laurie DiMiceli, Swaminathan Padmanabhan, David Lawrence, Zale P. Bernstein, Kenichi Takeshita, David Spaner, Paul Wallace, Catriona Byrne, Cynthia Crystal, Myron S. Czuczman
Journal: Blood (2005)
Nilotinib in Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia in Blast Crisis (CML-BC) Who Are Resistant or Intolerant to Imatinib.
Authors: Francis J. Giles, Richard A. Larson, Hagop M. Kantarjian, Philipp le Coutre, Michele Baccarani, Ariful Haque, Neil Gallagher, Oliver G. Ottmann
Journal: Blood (2007)
Outcomes and Impact of Donor Lymphocyte Infusion after Reduced Intensity Conditioned-Alemtuzumab Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Mature Lymphoid Malignancies
Authors: Charlotte K. Brierley, Francesca M Jones, Katherine Hanlon, Andrew Peniket, Patrick Medd, Andrew Clark, Anne Parker, Sridhar Chaganti, Ram Malladi, Charles Craddock, Robert Danby, Vanderson Rocha
Journal: Blood (2016)
Hitting the bullseye with a nonlethal payload: resistance in CD123-positive malignancies
Authors: Lukasz P. Gondek
Journal: Journal of Clinical Investigation (2019)

The interleukin 3 receptor (CD123) is a transmembrane protein that is absent or hardly expressed on normal hematopoietic stem cells, but highly expressed on the surface of cancer cells in several hematologic malignancies. In this issue of the JCI, Togami et al. investigated the mechanism of resistance to the recently approved anti-CD123 agent tagraxofusp, which consists of interleukin 3 fused to a truncated diphtheria toxin (DT) molecule. The authors demonstrated that loss of the intracellular target for DT, diphthamide, a conservative modification of histidine 715 in eukaryotic elongation factor 2, resulted in tagraxofusp resistance. Specifically, hypermethylation of the DPH1 gene, encoding a key enzyme in diphthamide synthesis, resulted in diphthamide loss. Notably, treatment with a DNA hypomethylating agent restored DPH1 expression and resensitized cells to tagraxofusp. The recognition of this resistance mechanism may have important clinical implications and lead to the development of more effective multiagent therapies.
Genome-Wide Mapping Reveals BRD4 in Regulation of Tumor-Driver Genes in Cutaneous T-Cell Lymphoma
Authors: Anjali Mishra, Alex Hartlage, Laura Sullivan, Leah Grinshpun, Sonya Kwiatkowski, Jun Qi, James E. Bradner, Pierluigi Porcu, Michael A. Caligiuri
Journal: Blood (2015)
Platelet CD36 Potentiates Thrombus Formation in Hyperlipidemic Conditions By Activating Redox Sensitive MAP Kinase ERK5
Authors: Moua Yang, Brian C. Cooley, Yiliang Chen, Jeannette M. Vasquez-Vivar, Na'il O. Scoggins, Scott J. Cameron, Craig N. Morrell, Roy L. Silverstein
Journal: Blood (2016)
Mast cell chymase protects against acute ischemic kidney injury by limiting neutrophil hyperactivation and recruitment
Authors: Lydia Celia Madjene, Luca Danelli, Albert Dahdah, Shamila Vibhushan, Julie Bex-Coudrat, Emeline Pacreau, Celine Vaugier, Julien Claver, Loïc Rolas, Maguelonne Pons, Iris Karina Madera-Salcedo, Walid Beghdadi, Alaa El Ghoneimi, Marc Benhamou, Pierre Launay, Magnus Abrink, Gunnar Pejler, Ivan Cruz Moura, Nicolas Charles, Eric Daugas, Axel Perianin, Ulrich Blank
Journal: Kidney International (2019)
Reliability of DCE MRI data in primary brain tumours: a comparison of Tofts and Shutter Speed Models
Authors: Marianna Inglese, Lesley Honeyfield, Eric Aboagye, Adam Waldman, Matthew Grech-Sollars
Journal: Neuro-Oncology (2019)

Abstract The accuracy of quantitative measurements of perfusion parameters by DCE-MRI is crucial as it can significantly impact the clinical care of cancer patients. In this study, we provide a method to identify reliable DCE-MRI brain data for perfusion quantification with different pharmacokinetic models. We analysed DCE-MRI data of 14 patients with primary brain tumours using the Tofts model (TM), the extended-Tofts model (ETM), the shutter speed model (SSM) and the extended shutter speed model (ESSM). Due to the presence of the blood brain barrier, which can block the leakage of the CA into the interstitium, we also implemented the no-exchange model (NEM). For each lesion, we produced a 3D model selection map with the evaluation of the Akaike Information Criteria. The variability of each pharmacokinetic parameter extracted from the fitting of the model of choice was assessed with a noise propagation procedure, resulting in distributions of the coefficient of variation (CV). Results showed the NEM to be the most frequent model of choice (35.5%), followed by the ETM (32%), the TM (28.2%), the SSM (4.3%) and the ESSM (&lt;0.1%). In analysing the reliability of Ktrans, when considering regions with a CV&lt;20%, ≈25% of voxels were found to be stable. The remaining 75% of voxels were considered to be unreliable. In conclusion, an appropriate model selection, considering tissue biology and its effects on BBB permeability and exchange conditions, together with an analysis on the reliability and stability of the calculated parameters, is critical in the identification of reliable brain DCE-MRI data.
Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Patients with a Negative Pet Scan Following Three Cycles of R-CHOP Can Be Effectively Treated with Abbreviated Chemoimmunotherapy Alone.
Authors: Laurie H. Sehn, Kerry J. Savage, Paul Hoskins, Richard Klasa, Tamara Shenkier, Nicholas Voss, Don Wilson, Joseph M. Connors
Journal: Blood (2007)
Overexpression of HIF-1α in Mesenchymal Stem Cells Contributes to Repairing Hypoxic-Ischemic Brain Damage in Rats
Authors: Qin Yu, Deju Lin, Liping Zhou, Biao Wang, Lizhen Liu, Chuanqin Hu, Fengjing Huang, Lixia Jiang
Journal: Blood (2016)
Phase II Trial of a Chemotherapy-Only Regimen of Busulfan, Melphalan, Fludarabine and R-ATG Followed by Allogeneic T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplants (HSCT) for the Treatment of Myeloid Malignancies.
Authors: Farid Boulad, Ann Jakubowski, Esperanza Papadopoulos, Katharine C. Hsu, Miguel Angel Perales, Marcel van den Brink, James W. Young, Michelle Chiu, Nancy A. Kernan, Susan E. Prockop, Andromachi Scaradavou, Trudy N. Small, Hugo Castro-Malaspina, Richard J. O’Reilly
Journal: Blood (2007)
Lysosomal Cell Death and Apoptosis Crosstalk - Synergistic Role in Bcl-2 Inhibitor (ABT-263) Mediated Cell Death in B-Cell Precursor Acute Lymphoblastic Leukemia
Authors: Stefanie Enzenmüller, Qian Sun, Klaus-Michael Debatin, Lüder-Hinrich Meyer
Journal: Blood (2016)
Electronic Cigarette Use Among Young, Middle-aged, and Older Adults in the United States in 2017 and 2018
Authors: Wei Bao, Buyun Liu, Yang Du, Linda G. Snetselaar, Robert B. Wallace
Journal: JAMA Internal Medicine (2019)

This study examines a trend in electronic cigarette use between 2017 and 2018 and stratifies results by sociodemographic categories.
Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines
Authors: Amy J. Johnson, Lisa L. Smith, Amy J. Wagner, Joshua Hessler, Joseph M. Flynn, Jeffrey A. Jones, Xiaoli Zhang, Amy Lehman, David Jarjoura, Michael R. Grever, Rajat Bannerji, John C. Byrd
Journal: Blood (2010)
Prognostic Impact and Concurrent Genetic Alterations of CEBPA Double Mutations in Adults with Cytogenetically Intermediate-Risk Acute Myeloid Leukemia.
Authors: Shunichiro Yamaguchi, Kenji Tokunaga, Eisaku Iwanaga, Tomoko Nanri, Taizo Shimomura, Hitoshi Suzushima, Hiroaki Mitsuya, Norio Asou
Journal: Blood (2012)
Introducing Fluorescence Guided Surgery into Neuro-Oncology Practice and Getting It Right First Time
Authors: Babar Vaqas, Ciaran Hill, Cathy Qin, Sophie Glover, Ruchi Maniar
Journal: Neuro-Oncology (2019)

Abstract Introduction Fluorescence Guided Surgery (FGS) using 5-ALA is recommended for patients undergoing resection of suspected high grade glioma and this type of surgery is increasingly being used in more units throughout the UK. We report on our experience of introducing 5-ALA guided surgery for suspected HGG in a regional neurosciences unit. Methods Consecutive series of the first 24 patients in our unit to receive 5-ALA guided surgery for suspected HGG from June 2017 to October 2018. Data was prospectively collected. Results 5-ALA fluorescence guided surgery was used for a range of histologically confirmed WHO grade III-IV gliomas. All but 1 tumour (GBM) fluoresced with 5-ALA, with strong fluorescence in recurrent GBM and anaplastic foci of grade 3 tumours. EOR varied according to the eloquence of the lesion with 70% of cases achieving gross total resection. 40% of cases used awake mapping or intraoperative neurophysiology. 5 patients (20.8%) had temporary neurological deficits which resolved in all cases. Individual surgeon learning curves resulted in 2 styles of practice- complete FGS with fluorescence used throughout the case, and intermittent use of fluorescence as an adjunct often at the end of debulking under white light. Conclusions Adopting 5-ALA use comes with specific challenges in terms of service organisation, learning curves and complication avoidance. Our experience is that it is useful both to improve EOR and as an adjunct to identify tumour tissue in eloquent region tumours with monitoring of function. This is possible through a day admission pathway in line with GIRFT.
Sustained perfusion of revascularized bioengineered livers heterotopically transplanted into immunosuppressed pigs
Authors: Mohammed F. Shaheen, Dong Jin Joo, Jeffrey J. Ross, Brett D. Anderson, Harvey S. Chen, Robert C. Huebert, Yi Li, Bruce Amiot, Anne Young, Viviana Zlochiver, Erek Nelson, Taofic Mounajjed, Allan B. Dietz, Gregory Michalak, Benjamin G. Steiner, Dominique Seetapun Davidow, Christopher R. Paradise, Andre J. van Wijnen, Vijay H. Shah, Mengfei Liu, Scott L. Nyberg
Journal: Nature Biomedical Engineering (2019)
BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy.
Authors: Paolo Vigneri, Fabio Stagno, Stefania Stella, Alessandra Cupri, Michele Massimino, Agostino Antolino, Vincenzo Abbadessa, Maura Brugiatelli, Patrizia Guglielmo, Caterina Musolino, Diamante Turri, Mario Russo, Guido Pagnucco, Michele Rizzo, Maurizio Musso, Fortunato Morabito, Luciano Levato, Angelo Messina, Francesco Di Raimondo
Journal: Blood (2010)
Phase I Trial of Suberoylanilide Hydroxamic Acid (SAHA) + Bortezomib (Bort) in Relapsed Multiple Myeloma (MM) Patients (pts).
Authors: Ashraf Badros, S. Philip, R. Niesvizky, O. Goloubeva, C. Harris, J. Zweibel, J. Wright, A. Burger, S. Grant, M.R. Baer, M.J. Egorin
Journal: Blood (2007)
Integrated Genomic Analysis of Down Syndrome Acute Lymphoblastic Leukemia Reveals Recurrent Cancer Gene Alterations and Evidence of Frequent Subclonal Driver Events
Authors: Oliver A, Hampton, Enrique I. Ramos, Nipun Kakkar, Jacob J. Junco, Jacquelyn Reuther, Anne Angiolillo, Reuven J Schore, Michael J. Burke, Wanda Salzer, Meenakshi Devidas, Andrew J. Carroll, Nyla A. Heerema, Kelly Maloney, Naomi Winick, William L. Carroll, Elizabeth Raetz, Mignon L. Loh, Stephen P. Hunger, Juhi Jain, Harsha Doddapaneni, Donna M. Muzny, David A. Wheeler, Kevin E. Fisher, Dolores H. Lopez-Terrada, Angshumoy Roy, Donald Williams Parsons, Karen R. Rabin
Journal: Blood (2016)
The Purine Nucleoside Phosphorylase Inhibitor Forodesine (BCX-1777) Is a Potent Cytotoxic Agent and Has Synergistic Activity with Bendamustine in Chronic Lymphocytic Leukemia (CLL) Irrespective of ZAP-70 Levels and p53 Status.
Authors: Roberto Alonso, Neus Villamor, Ramanda Upshaw, Shanta Bantia, Thomas Mehrling, Elias Campo, Emili Montserrat, Dolors Colomer
Journal: Blood (2007)
First Line BR in Chronic Lymphocytic Leukemia Patients: Interim Results of Russian Norma Trial
Authors: Elena Stadnik, Vladimir Strugov, Tatyana Silina, Natalya Ilyina, Yulia Virts, Renat Badaev, Galina Kuchma, Elena Volodicheva, Tatyana Sycheva, Tatyana Kaporskaya, Kamil Kaplanov, Natalya Glonina, Lyubov Anchukova, Tatyana Byalik, Olga Samoilova, Elena Kirillova, Sergey Shklyaev, Yulia Mirolubova, Tatyana Nikulina, Andrey Rumyantsev, Andrey Proydakov, Irina Lysenko, Vladimir Melnichenko, Natalya Esefeva, Tatyana Ksenzova, Igor Davidkin, Olga Vasilyeva, Oksana Ochirova, Oleg Rukavitsyn, Natalya Bulieva, Vera Zherebtsova, Andrey Gubkin, Yulia Bogdanova, Irina Chebykina, Elena Shukaeva, Andrey Zaritskey
Journal: Blood (2014)
Establishment and Characterization of an Ig Lambda Secreting Cell Line from a Patient with AL Amyloidosis.
Authors: Bonnie K. Arendt, Gregory J. Ahmann, Erin M. Mulvihill, Laura A. Sikkink, Angela Dispenzieri, Marina Ramirez-Alvarado, Steven R. Zeldenrust, Rafael Fonseca, Diane F. Jelinek
Journal: Blood (2006)
Sustained Natural Killer Cell Recovery Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation Predicts Survival in Non-Hodgkin's Lymphoma
Authors: Luis Porrata, David James Inwards, Stephen M Ansell, Ivana Micallef, Patrick B. Johnston, Wendy Nevala, Svetomir Markovic
Journal: Blood (2016)
The Nitric Oxide-Generating Prodrug Js-K Is Selectively Toxic Towards AML Compared to Normal Human Hematopoietic Cells
Authors: Kristi J. Smock, William L. Heaton, Anthony D. Pomicter, Ronda A Crist, Ken M Kosak, Kenneth M Boucher, George M. Rodgers, Thomas O'Hare, Michael W. Deininger, Paul J Shami
Journal: Blood (2016)
Primary Central Nervous System Lymphoma – Management and Outcome in the ‘haematology era’
Authors: Siddhant Kumar, Abdurrahman Islim, Tamara Ali, Jeffery Smith, Brian Haylock, Aditya Shenoy, David Husband, Samantha J Mills, Andrew Brodbelt, Emmanuel Chavredakis, David Lawson, Grace Chapman, Nawani Wickramaratne, Adam Ridzuan-Allen, Imogen Harrison, Michael D Jenkinson
Journal: Neuro-Oncology (2019)

Abstract Introduction Primary CNS lymphoma (PCNSL) requires a biopsy for diagnosis but can be inconclusive when steroids are administered. Without treatment median survival is 1.5–3.3 months, improving to 10–20 months with oncological treatment. This study aimed to compare outcomes of PCNSL treated under haematology to those of clinical oncologists. Methods Retrospective casenote review of patients with PCNSL treated under oncologists (2006–2010) and haematologists (2011–2016). Results 121 cases were identified (median age 63 years; range 19–84). Median WHO performance status (PS) was 1. 11.6% required repeat biopsy. 10 patients were managed palliatively due to poor PS. 67 cases were managed under haematology. Median symptom duration was 28 days (range 2–540). Median time from MRI to diagnosis was 18 days (range 6–232). 66 patients received chemotherapy, 1 received radiotherapy. Median overall survival (OS) was 8 months (95%CI: 0.7–15.3), 5-year OS was 22.4%. 44 cases were managed under oncology. Median symptom duration was 28 days (range 2–365). Median time from MRI to diagnosis was 16 days (range 6–309). 34 patients received radiotherapy first-line, 10 received chemotherapy. Median OS was 7 months (95%CI: 0–21.5), 5-year OS was 15.9%. Multivariate analysis demonstrated PS (HR 2.02 (95%CI: 1.08–3.76)) and symptom duration (HR 0.63 (95%CI: 0.41–0.96)) to be significant prognostic indicators for OS. Discussion PCNSL carries poor prognosis and outcomes from the ‘haematology era’ are similar to those achieved by clinical oncologists. Delay in diagnosis leads to worse outcomes and highlights the ongoing need to streamline current clinical services to improve outcomes.
Endogenous TGF-beta1 Mediated Osteogenic Impairment of Medullar Mesenchymal Stromal Cells in Primary Myelofibrosis
Authors: Christophe Martinaud, Christophe Desterke, Johanna Konopacki, Lisa Pieri, Rachel Golub, Sandrine Schmutz, Adrienne Anginot, Bernadette Guerton, Nathalie Rochet, Patricia Albanese, Emilie Henault, Thierry De Revel, Marie-Françoise Bourgeade, Vanucchi Alessandro, Jean-Jacques Lataillade, Marie-Caroline Le Bousse-Kerdilès
Journal: Blood (2014)
MTHFR-A1298C Polymorphism Is Associated with Veno-Occlusive Disease (VOD) and Liver Toxicity after Busulfan/Cyclophosphamide Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Eray Goekkurt, Jan Stoehlmacher, Christian Stueber, Christine Wolschke, Tatjana Zabelina, Thomas Eiermann, Thomas Binder, Simona Iacobelli, Axel R. Zander, Nicolaus Kröger
Journal: Blood (2005)
ABO Mismatch Adversely Affects GvHD In Recipients of HLA Matched Unrelated Marrow or Peripheral Blood but Not Single or Double Umbilical Cord Blood Transplants
Authors: Rizwan Romee, Daniel J. Weisdorf, Claudio Brunstein, John E. Wagner, Bruce R. Blazar, Navneet S. Majhail, Gregory M. Vercellotti, Jeffrey S. Miller, Mukta Arora
Journal: Blood (2010)
Hematopoietic Size Control: A Novel Role for Factor VIII Via the Thrombin/PAR1 Axis in Regulating the Interplay Between Dynamic Bone Structure and Long Term Survival and Mobilization of Hematopoietic Stem Cells
Authors: Anna Aronovich, Yaniv Nur, Chava Rosen, Yael Klionsky, Liran Yarimi, David Hagin, Gideon Rechavi, Uriel Martinowitz, Dalit Tchorsh–Yutsis, Yair Reisner
Journal: Blood (2011)
CD16+CD56− NK Cells in the Peripheral Blood of Cord Blood Transplant Recipients: A Unique Subset of Immature NK Cells Possibly Associated with Graft-Versus-Leukemia Effect.
Authors: Xuzhang Lu, Yokio Kondo, Hiroyuki Takamatsu, Hiroshita Yamazaki, Zhirong Qi, Kinya Ohata, Luis Espinoza, Yoshik Akasuka, Shinji Nakao
Journal: Blood (2007)
Management Evaluation of Metastasis in the Brain (MEMBRAIN) – A UK &amp; Ireland prospective, multicentre observational study
Authors: Josephine Jung, Jignesh Tailor, Emma Dalton, Laurence J Glancz, Joy Roach, Rasheed Zakaria, Simon P Lammy, Aswin Chari, Karol P Budohoski, Laurent J Livermore, Kenny Yu, Michael D Jenkinson, Paul M Brennan, Lucy Brazil, Catey Bunce, Keyoumars Ashkan, Francesco Vergani
Journal: Neuro-Oncology (2019)

Abstract Background Over the recent years an increasing number of patients with brain metastasis are being referred to the neuro-oncology multi-disciplinary team (NMDT). Our aim was to determine if referrals of this group of patients to the NMDT in the UK &amp; Ireland comply with NICE guidelines and to assess referral volume, quality of information provided and its impact on NMDT decision-making. Methods Prospective multicentre oberservational study including all adult patients referred with ≥1 cerebral metastasis. Data was collected in neurosurgical units from 11/2017 to 02/2018. Demographics, primary disease, Karnofsky performance status (KPS), imaging and treatment recommendation were entered into an online database. Results 1049 patients were analysed from 24 neurosurgical units. Median age was 63[range 21–93] years with a median number of 3[range 1–17] referrals per NMDT. The most common primary malignancies were lung (36.5%, n=383), breast (18.5%, n=194) and melanoma (12.0%, n=126). 51.6% (n=541) of the referrals to the NMDT were within the NICE 2006 guidelines, and resulted in specialist intervention being offered in 68.8%. 41.2% (n=197) of patients being referred outside of the NICE 2006 guidelines were offered specialist treatment. NMDT decision-making was influenced by number of metastases, age, KPS, primary disease status and extent of extracranial disease (univariate logistic regression, p&lt;0.0001) as well as metastasis location/histology (p&lt;0.05). Conclusions This study confirmed a national change in culture of referral patterns. We identified a delay in NMDT decision-making in ~20%, contributing to increased NMDT workload. New stratification tools may be needed to reflect advancements in diagnostics and treatment modalities.
Results of a Prospective Clinical Trial of Pre-DLI Lymphoreduction Using Oral Fludarabine In Patients with Mixed Chimerism Post Allogeneic Transplant.
Authors: Bronwen E. Shaw, Jenny Byrne, Emma Das-Gupta, Mark Ethell, Daniel Figueroa, J. Alejandro Madrigal, Gareth J Morgan, Sameer Tulpule, Michael Potter, Nigel H. Russell
Journal: Blood (2010)